Published in Curr Pharm Des on January 01, 2009
Antihypertensive drugs and glucose metabolism. World J Cardiol (2014) 0.87
Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice. Lab Invest (2010) 0.84
Modulation of lipid metabolic defects rescues cleft palate in Tgfbr2 mutant mice. Hum Mol Genet (2013) 0.80
Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study. Drug Des Devel Ther (2016) 0.75
Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) (2007) 2.22
Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract (2009) 2.20
Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med (2000) 2.11
Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology (2009) 1.48
Mechanisms of hyponatraemia in alcohol patients. Alcohol Alcohol (2001) 1.34
How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf (2009) 1.31
Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J (2011) 1.18
Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur J Clin Invest (2005) 1.15
Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) (2008) 1.12
Lipoprotein (a) and chronic obstructive pulmonary disease. Atherosclerosis (2000) 1.07
Visceral leishmaniasis resembling systemic lupus erythematosus. Ann Rheum Dis (2004) 1.06
Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J Endocrinol (2001) 1.04
Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest (2008) 1.04
Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest (2007) 1.00
Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology (Oxford) (2007) 0.99
Diagnosis and management of the metabolic syndrome in obesity. Obes Rev (2005) 0.98
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis (2006) 0.95
Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev (2007) 0.95
Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother (2008) 0.95
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab (2007) 0.93
Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. J Hum Hypertens (2007) 0.93
Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev (2008) 0.93
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin (2005) 0.92
A review of the metabolic effects of sibutramine. Curr Med Res Opin (2005) 0.92
Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med (2005) 0.91
Fibrinogen: a predictor of vascular disease. Curr Pharm Des (2007) 0.91
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin (2008) 0.90
Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets (2006) 0.90
Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis (2006) 0.90
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling. Curr Med Res Opin (2001) 0.89
Do statins have an antiarrhythmic activity? Cardiovasc Res (2007) 0.89
Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr Metab Cardiovasc Dis (2011) 0.89
Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin (2008) 0.87
Elevated interleukin-1 beta in the circulation of patients with essential hypertension before any drug therapy: a pilot study. Eur J Clin Invest (1996) 0.87
Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis (2007) 0.87
Hypernatremia in hospitalized patients: a sequel of inadvertent fluid administration. Arch Intern Med (2000) 0.86
Statins: another class of antihypertensive agents? J Hum Hypertens (2006) 0.86
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother (2008) 0.85
Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract (2008) 0.84
Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Int J Clin Pract (2007) 0.84
Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother (2008) 0.84
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol (2000) 0.83
The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids (2010) 0.83
Acid-base and electrolyte abnormalities in patients with acute leukemia. Am J Hematol (1999) 0.83
The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab (2005) 0.82
Appropriate treatment of hypernatraemia in diabetic hyperglycaemic hyperosmolar syndrome. J Intern Med (2001) 0.82
Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension. Curr Vasc Pharmacol (2010) 0.82
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother (2008) 0.82
Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis (1999) 0.81
Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes. Atherosclerosis (2010) 0.81
Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J (2010) 0.81
Renal abnormalities in patients with sickle cell-beta thalassemia. J Nephrol (1997) 0.81
Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother (2008) 0.81
Does the presence of metabolic syndome influence weight loss in obese and overweight women? Metab Syndr Relat Disord (2010) 0.81
Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease. J Cardiovasc Risk (2001) 0.80
Hypersensitivity syndrome caused by amitriptyline administration. Postgrad Med J (2000) 0.80
Absence of SLC22A12 gene mutations in Greek Caucasian patients with primary renal hypouricaemia. Scand J Clin Lab Invest (2007) 0.80
Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr Pharm Des (2008) 0.79
Statin treatment may be beneficial to both the kidneys and the heart. Perit Dial Int (2007) 0.79
High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids (2011) 0.79
Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. Int J Clin Pract (2013) 0.79
Severe hypophosphatemia in a patient with acute pancreatitis. JOP (2000) 0.78
Adult cardiovascular risk factors in premature babies. Lancet (2000) 0.78
Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scand J Rheumatol (2013) 0.78
Platelet function and lipid-lowering interventions. Platelets (1999) 0.78
Acid-base abnormalities in a patient with hepatic cirrhosis. Nephrol Dial Transplant (1999) 0.78
Statins for non-alcoholic fatty liver disease: a new indication? Aliment Pharmacol Ther (2006) 0.78
Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. Fundam Clin Pharmacol (2001) 0.78
Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk (1999) 0.78
Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res (2009) 0.78
Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus. Diabetes Metab (2001) 0.78
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract (2012) 0.78
Lipoprotein (a) levels, apolipoprotein (a) phenotypes and thyroid autoimmunity. Eur J Endocrinol (1999) 0.78
Lysis syndrome during therapy of visceral leishmaniasis. Infection (2011) 0.78
Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens (2011) 0.77
Serum potassium and acid-base parameters in severe dialysis-associated hyperglycemia treated with insulin therapy. Int J Artif Organs (2005) 0.77
Syndrome of inappropriate antidiuretic hormone secretion due to recurrent oral cancer. B-ENT (2005) 0.77